U.S. markets close in 47 minutes
  • S&P 500

    +3.68 (+0.09%)
  • Dow 30

    -177.97 (-0.52%)
  • Nasdaq

    +143.97 (+1.03%)
  • Russell 2000

    -29.76 (-1.29%)
  • Crude Oil

    -1.02 (-1.41%)
  • Gold

    -82.40 (-4.43%)
  • Silver

    -1.78 (-6.39%)

    -0.0089 (-0.74%)
  • 10-Yr Bond

    -0.0600 (-3.82%)

    -0.0059 (-0.42%)

    -0.3350 (-0.30%)

    -1,070.89 (-2.76%)
  • CMC Crypto 200

    -33.24 (-3.43%)
  • FTSE 100

    -31.52 (-0.44%)
  • Nikkei 225

    -272.68 (-0.93%)

Some Nuvo Pharmaceuticals (TSE:NRI) Shareholders Have Taken A Painful 85% Share Price Drop

·3 min read

Nuvo Pharmaceuticals Inc. (TSE:NRI) shareholders will doubtless be very grateful to see the share price up 88% in the last quarter. But that is meagre solace in the face of the shocking decline over three years. In that time the share price has melted like a snowball in the desert, down 85%. So it's about time shareholders saw some gains. But the more important question is whether the underlying business can justify a higher price still.

We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.

See our latest analysis for Nuvo Pharmaceuticals

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

Nuvo Pharmaceuticals has made a profit in the past. However, it made a loss in the last twelve months, suggesting profit may be an unreliable metric at this stage. Other metrics may better explain the share price move.

Revenue is actually up 20% over the three years, so the share price drop doesn't seem to hinge on revenue, either. It's probably worth investigating Nuvo Pharmaceuticals further; while we may be missing something on this analysis, there might also be an opportunity.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

TSX:NRI Income Statement, February 18th 2020
TSX:NRI Income Statement, February 18th 2020

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

Investors in Nuvo Pharmaceuticals had a tough year, with a total loss of 65%, against a market gain of about 8.8%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 25% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Nuvo Pharmaceuticals , and understanding them should be part of your investment process.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on CA exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.